Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00851955
Recruitment Status : Completed
First Posted : February 26, 2009
Last Update Posted : January 12, 2016
Sponsor:
Information provided by (Responsible Party):
Massimo Raimondo, M.D., Mayo Clinic

Brief Summary:
The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.

Condition or disease
Chronic Pancreatitis Pancreatic Cancer

Layout table for study information
Study Type : Observational
Actual Enrollment : 150 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
Study Start Date : May 2007
Actual Primary Completion Date : December 2009
Actual Study Completion Date : November 2011

Resource links provided by the National Library of Medicine


Group/Cohort
1. Normal pancreas patients
Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
2. Chronic pancreatitis patients
Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
3. Pancreatic cancer patients
Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.



Primary Outcome Measures :
  1. All cause mortality [ Time Frame: One year ]

Secondary Outcome Measures :
  1. For pancreatic patients from whom tissue samples will be available, we will examine the association between presence/absence of each marker in the tissue versus the marker level in blood and in pancreatic juice. [ Time Frame: One year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Primary Care
Criteria

Inclusion Criteria:

  • Normal subjects - No documented clinical history of pancreatic diseases supported by at least 1 negative imaging test. (EUS, Ct scan or MRI)
  • Chronic pancreatitis - Documented diagnosis of moderate to advanced chronic supported bpancreatitisy at least 1 positive imaging test. (EUS, Ct scan or MRI)
  • Pancreatic Cancer - Documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.

Exclusion Criteria:

  • Exclusion criteria will include age younger than 18 yrs, pregnancy, previous pancreatic or gastric resection, and inability to tolerate routine endoscopy with conscious sedation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00851955


Locations
Layout table for location information
United States, Florida
Mayo Clinic
Jacksonville, Florida, United States, 32224
Sponsors and Collaborators
Mayo Clinic
Investigators
Layout table for investigator information
Principal Investigator: Massimo Raimondo, MD Mayo Clinic

Layout table for additonal information
Responsible Party: Massimo Raimondo, M.D., PI, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00851955    
Other Study ID Numbers: 07-000099
First Posted: February 26, 2009    Key Record Dates
Last Update Posted: January 12, 2016
Last Verified: January 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Pancreatitis
Pancreatitis, Chronic
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases